{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-031028","form_type":"8-K","ticker":"LSTA","cik":"0000320017","company_name":"LISATA THERAPEUTICS, INC.","filed_at":"2026-08-04T10:01:26+00:00","discovered_at":"2026-08-04T10:10:02.144339+00:00","generated_at":"2026-08-04T10:10:58.720882+00:00","sec_items":["2.05","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lisata Therapeutics cuts 72% of workforce, sues Kuva Labs over merger breach","bullets":["Workforce reduced by ~72% effective immediately; estimated $1.2M in severance costs through Q3 2026.","CMO Dr. Kristen K. Buck terminated without cause; entitled to 12 months salary and bonus plus COBRA.","Company sued Kuva Labs in Delaware Chancery for breach of March 2026 merger agreement, seeking damages.","Retention bonus of $200k approved for SVP James Nisco, contingent on employment through Dec 31, 2026.","Company plans to pursue strategic options to maximize shareholder value."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-031028","json":"https://secwatch.observer/filing/0001140361-26-031028.json","markdown":"https://secwatch.observer/filing/0001140361-26-031028.md","text":"https://secwatch.observer/filing/0001140361-26-031028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/320017/000114036126031028/0001140361-26-031028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/320017/000114036126031028/ef20079399_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T10:10:58.720882+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}